CARM1 Arginine Methyltransferase as a Therapeutic Target for Cancer.

CARM1 is an arginine methyltransferase that post-translationally modifies proteins that regulate multiple levels of RNA production and processing. Its substrates include histones, transcription factors, co-regulators of transcription and splicing factors. CARM1 is overexpressed in many different cancer types, and often promotes transcription factor programs that are co-opted as drivers of the transformed cell state, a process known as transcription factor addiction. Targeting these oncogenic transcription factor pathways is difficult but could be addressed by removing the activity of the key coactivators on which they rely. CARM1 is ubiquitously expressed, and its knockout is less detrimental in embryonic development than deletion of the arginine methyltransferases PRMT1 and PRMT5, suggesting that therapeutic targeting of CARM1 may be well tolerated. Here, we will summarize the normal in vivo functions of CARM1 that have been gleaned from mouse studies, expand on the transcriptional pathways that are regulated by CARM1, and finally highlight recent studies that have identified oncogenic properties of CARM1 in different biological settings. This review is meant to kindle an interest in the development of human drug therapies targeting CARM1, as there are currently no CARM1 inhibitors available for use in clinical trials.